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Survival rates for patients with epithelial ovarian cancer have
shown some improvement in the past decade but remain unsatis-
factory (Yokoyama et al, 1999). Generally accepted clinical and
pathological prognostic parameters for epithelial ovarian cancers
are stage, histologic subtypes and grades, and residual tumour
after cytoreductive surgery (Yokoyama et al, 1999). Although
biological and genetic parameters, such as macrophage colony-
stimulating factor (Chambers et al, 1997), vascular endothelial
growth factor (VEGF) (Tempfer et al, 1998), p53 (Werness et al,
1999), and other oncogenes (Silverberg, 1999) have recently been
identified as prognostic factors in epithelial ovarian cancers, there
is a lack of clinically useful molecular markers for assessing
prognosis in ovarian cancer. 
Loss of carbonyl reductase (CR) expression in a mouse lung
adenocarcinoma cell line has been demonstrated to augment the
cells’ metastatic capacity (Ismail et al, 2000). Moreover, recent
immunohistochemical study has revealed that the combined rate
for weakly positive and negative reactions for CR was propor-
tional to the degree of dedifferentiation in hepatocellular cancers
(Suto et al, 1999). These results suggest the possibility that
decrease or loss of CR by some mechanism might render the
tumour cells more malignant than their intrinsic nature. 
CR is a cytosolic monomeric, NADPH-dependent oxidoreduc-
tase with broad specificity for carbonyl compounds (Lopez de
Cerain et al, 1999). It has been isolated from a number of human
tissues: brain, liver, breast, ovary, and placenta (Wermuth, 1981;
Wermuth et al, 1988; Iwata et al, 1990), and has been therefore
implicated in the metabolism of a variety of endogenous and
xenobiotic carbonyl compounds: prostaglandins (Lee and Levine,
1974) and anthracycline antibiotics such as daunorubicin (Ahmed
et al, 1978). Prostaglandins have been demonstrated not only to
modulate apoptosis and bcl-2 expression (Sheng et al, 1998) but
also to induce angiogenesis (Tsujii et al, 1998). 
In the present study, the expression of CR in epithelial ovarian
cancer tissues was immunohistochemically investigated in order to
examine the relationship between its expression and clinical-
pathological prognostic factors and chemosensitivity. 
MATERIALS AND METHODS 
Patients and tissues 
Fresh surgical specimens of ovarian cancer were obtained from 73
patients who were treated at Hirosaki University Hospital between
April of 1988 and December of 1998, after informed consent had
been obtained. All patients were surgically staged in accordance
with the 1988 International Federation of Gynecology and
Obstetrics (FIGO) criteria. Namely, they underwent surgery for a
total hysterectomy, bilateral salpingo-oophorectomy, partial omen-
tectomy, appendectomy, and pelvic and para-aortic lymphadenec-
tomies. The breakdown for stages of ovarian cancer consisted of
36 patients with stage I, 9 with stage II, 21 with stage III, 7 with
stage IV. Histological types were classified into 30 cases with
serous cystadenocarcinoma, 17 with mucinous cystadenocarci-
noma, 15 with endometrioid adenocarcinoma, 8 with clear cell
adenocarcinoma, 3 with undifferentiated adenocarcinoma. All the
patients received postoperative chemotherapy combining cisplatin
60 mg m–2, epirubicin 40 mg m–2, and cyclophosphamide 300
mg m–2 (PAC). In addition, surgical specimens were obtained
from 13 women with borderline malignant tumour of the ovary
and from 25 women with benign ovarian tumour. 
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Anti-CR antibody was prepared in a rabbit as reported previously
(Kajihara-Kano et al, 1997). All samples surgically obtained for
immunohistochemistry were immediately fixed in formaldehyde
and embedded in paraffin. Sections 6 µ m thick were routinely
passed through xylene and a graded alcohol series and stained for
CR by the labelled streptavidin biotin method (LSAB kit; DAKO,
Santa Barbara, CA) using anti-CR antibody as reported previously
(Yokoyama et al, 2000). Anti-CR antibody was applied for 12 h at
4˚C in a moist chamber. The binding sites of peroxidase were
determined using 3,3′ -diaminobenzidine as the substrate. The
sections were then counterstained with haematoxylin for micro-
scopic examination. As negative control, preimmune rabbit serum
or antibody preparation absorbed with the antigen was used
instead of the antibody. As positive control for CR staining,
formalin-fixed paraffin-embedded sections of normal human liver
were stained by the same procedure (Suto et al, 1999). 2 observers
independently evaluated and interpreted the results of
immunohistochemical staining, without knowledge of the clinical
data of each patient. Immunohistochemical staining was evaluated
according to a scoring method reported previously (Yokoyama
et al, 2000). Namely, a score was established corresponding to the
sum of: (1) the percentage of positive cells (0, 0% immunopositive
cells; 1, < 25% positive cells; 2, 26–50% positive cells; and 3,
> 50% positive cells); and (2) the staining intensity (0, negative; 1,
weak; 2, moderate; 3, high). The sum for the assigned values of the
positive cell percentage (1) and the staining intensity (2) was 6 or
less than 6. Scores between 0 and 2 were regarded as negative,
scores of 3 and 4 as weakly positive, and scores of 5 and 6 as
strongly positive. 
Statistical analysis 
The survival curves were calculated by the Kaplan–Meier method,
and the statistical significance of differences in the cumulative
survival curves between the groups was evaluated by Cox–Mantel
test. Other statistical analyses were carried out by Chi-square test
or Fisher’s exact probability test. A result was deemed significant
at P < 0.05. 
RESULTS 
Expression of CR in benign tumour, borderline
malignant tumour and cancer 
The frequencies of expression of CR in benign tumour, borderline
malignant tumour and cancer are demonstrated in Table 1. There
was no significant difference in the rates of CR positivity between
samples of benign tumour and borderline malignant tumour. The
incidence of CR expression (weakly positive and strongly posi-
tive) in cancers (45 out of 73, 61.6%) was significantly higher than
that in benign tumours (8 out of 25, 32.0%) (P < 0.01). CR was in
general homogeneously stained in the cytoplasm of positive cases
(Figure 1). 
Relationship between CR expression and 
clinico-pathological factors in ovarian cancers 
The correlation between CR expression and clinico-pathological
factors in ovarian cancers is displayed in Table 2. CR expression
had no correlation to clinical stage, histological type and histolog-
ical grade. On the other hand, there was an inverse correlation
between CR expression and RLN metastasis, namely, the CR-
positive rate was 35.7% (weakly positive alone) for ovarian
cancers with RLN metastasis and 67.8% for those without RLN
metastasis, the former being significantly lower than the latter (P <
0.05). Moreover, CR expression in metastatic lymph nodes was
weaker with a marginal significance (P = 0.086) than that in the
primary lesions (Table 3). There was no significant difference in
CR expression between the intraperitoneal or pelvic disseminated
foci and those primary lesions (Table 3). 
Of the 73 patients, 25 had drug resistance, 12 of whom under-
went the resection of the remaining or recurrent tumours. There
was no significant difference in CR expression between the 12
resected tumours and those primary lesions. 
Survival of patients with ovarian cancer according to
CR expression 
5-year survival rate of patients with CR weakly or strongly posi-
tive cancer was 86.1% and that of those with CR-negative one was
62.7%. The prognosis for patients with CR negative cancer was
significantly poorer than that for those with CR weakly or strongly
positive cancer (Figure 2, P < 0.05). 
DISCUSSION 
We have recently reported a novel function for CR, namely, its
ability to modulate the metastatic potential of malignant mouse
cells (Ismail et al, 2000). We have shown that carbonyl reductase
mRNA was not detectable in the sub-line with high metastatic
capacity derived from a mouse lung adenocarcinoma cell line,
whereas it was present at high abundance in the sub-line with low
metastatic capacity derived from the same one (Ismail et al, 2000).
Furthermore, transfection of the low metastatic-potential subline
with a construct expressing antisense carbonyl reductase rendered
the cells highly metastatic, and conversely transfection of the high
metastatic-potential subline with a construct expressing sense
carbonyl reductase decreased their metastatic capacity markedly
(Ismail et al, 2000). Recent immunohistochemical examination
also demonstrated that decreased expression of CR in hepatocel-
lular cancers was proportional to the degree of dedifferentiation
(Suto et al, 1999). In the present study, although intensity of CR
expression in epithelial ovarian cancer was unrelated to the histo-
logical grade, decrease or loss of CR expression in epithelial
ovarian cancer significantly correlated with RLN metastasis.
These results suggest an important function for CR in modulating
the metastatic potential of malignant tumour. 
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Table 1 Correlation between expression of carbonyl reductase (CR) and
ovarian neoplasms 
CR expression (%)
Tissues No. of
Negative Weakly Strongly patients
positive positive
Benign tumour 25 17 (68.0) 7 (28.0) 1 (4.0) 
Borderline malignancy 13 8 (61.5) 3 (23.1) 2 (15.4) 
Cancer 73 28 (38.4) 32 (43.8) 13 (17.8) 
Statistical significance is described in detail in the text. 
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CR has been found to be biochemically, immunologically and
functionally identical to prostaglandin 9-ketoreductase (PG 9-KR)
(Schieber et al, 1992). PG 9-KR oxidises prostaglandin E2, F2α and
D2 to biologically inactive 15-keto metabolites (Schieber et al,
1992). Prostaglandins play an important role in modulating tumour
growth and metastasis in a variety of human tumours (Ablin and
Shaw, 1986). Prostaglandin E2 has been shown to have important
functions in inducing angiogenesis (Tsujii et al, 1998) as well as in
inhibiting apoptosis (Sheng et al, 1998) in cancer cells. Our recent
immunohistochemical study revealed a significant relationship
Figure 1 Immunohistochemical staining of carbonyl reductase in epithelial ovarian cancers. A, B, C and D demonstrate positive control in normal liver,
negative, weakly positive and strongly positive staining, respectively, in epithelial ovarian cancer tissues. Original magnification, × 200 
Table 2 Relationship between expression of carbonyl reductase and clinico-pathological factors in
ovarian cancer 
Factors
No. of
CR expression (%)
patients Negative Weakly Strongly
positive positive
Stage 
I and II 45 17 (37.8) 18 (40.0) 10 (22.2) 
III and IV 28 11 (39.8) 14 (50.0) 3 (10.7) 
Histological type 
Serous 30 12 (40.0) 13 (43.3) 5 (16.7) 
Mucinous 17 7 (41.2) 7 (41.2) 3 (17.6) 
Endometrioid 15 5 (33.3) 8 (53.3) 2 (13.4) 
Clear cell 8 3 (37.5) 3 (37.5) 2 (25.0) 
Undifferentiated 3 1 (33.3) 1 (33.3) 1 (33.3) 
Grade 
Well 42 16 (38.1) 19 (45.2) 7 (16.7) 
Moderate 16 6 (37.5) 8 (50.0) 2 (12.5) 
Poor 7 3 (42.8) 2 (28.6) 2 (28.6) 
Lymph node metastasis 
– 59 19 (32.2) 27 (45.8) 13 (22.0) 
+ 14 9 (64.3) 5 (35.7) 0 
Statistical significance is described in detail in the text. 
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between RLN involvement and the expression of Flt-4 in endome-
trial cancers and a marginally significant correlation between RLN
involvement and VEGF expression, suggesting that VEGF-Flt-4
system might promote lymph-angiogenesis and lymph node
metastasis in endometrial cancer (Yokoyama et al, 2000). 
CR metabolizes a variety of antitumour drugs containing carbonyl
groups, such as the anthracycline antibiotics, daunorubicin and
doxorubicin (Ahmed et al, 1978). CR reduces the methyl ketone in
the carbon side-chain of daunorubicin to its corresponding alcohol
(Kuffel et al, 1992). It has been previously suggested that high CR
activity found in some tumour cells might contribute to tumoural
resistance to some drugs metabolized in such a way (Lopez de
Cerain et al, 1999). The present results, however, demonstrated no
significant difference in CR expression between the chemosensitive
ovarian cancers and the chemoresistant ones, suggesting that there
might be little connection between drug resistance and CR expres-
sion in epithelial ovarian cancer. It should be noted that the key anti-
cancer drug for epithelial ovarian cancer treatment is broadly known
to be cisplatin, however, it remains to be determined whether CR
activity affects metabolism of cisplatin in vivo. 
In conclusion, the present results indicate that decreased CR
expression in epithelial ovarian cancer tissues is associated with
RLN metastasis and poor survival. This is the first study in any
human cancer to show a strong correlation between survival and
CR level and supports a more important role for CR in human
tumours than has been previously thought. Further studies are
urgently needed to clarify the precise mechanisms by which CR
alters the metastatic potential of cancer cells. 
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